Nurix Therapeutics, Inc.

NRIX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$25.70-4.12%

2026-11-02

Financials

Valuation Metrics

Nurix Therapeutics, Inc.'s Market Cap is $2.66B. At end of 2025 it was $2.09B. Ranked #1756 of 3,118 in US market (top 56%), #627 of 1,474 on NASDAQ (top 43%), #109 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$2.66B	US#1,756/3,118 Sec#109/265
Revenue	$702M	US#2,077/3,118 Sec#68/265
Net Income	$295M	US#1,091/3,118 Sec#37/265
Total Assets	$1.20B	US#2,384/3,118 Sec#87/265
Net Assets	$968M	US#1,775/3,118 Sec#67/265
Value
P/E	9.01x	US#289/3,118 Sec#9/265
P/B	2.74x	US#1,717/3,118 Sec#93/265
P/S	3.79x	US#2,065/3,118 Sec#65/265
EV/EBITDA	6.21x	US#350/3,118 Sec#11/265
FCF Yield	13.92%	US#352/3,118 Sec#12/265
Profitability
ROE	30.45%	US#289/3,118 Sec#17/265
ROA	24.67%	US#62/3,118 Sec#13/265
Op. Margin	41.27%	US#252/3,118 Sec#15/265
Revenue Growth	738.76%	US#21/3,118 Sec#12/265
Financial Health
Debt Ratio	23.44%	US#262/3,118 Sec#86/265
Total Debt	$65M	US#2,543/3,118 Sec#143/265
FCF	$370M	US#1,041/3,118 Sec#37/265
Cash	$720M	US#853/3,118 Sec#39/265
Current Ratio	8.44x	US#297/3,118 Sec#88/265
Net Debt/EBITDA	-2.03x	US#170/3,118 Sec#11/265
Performance
1Y Return	98.57%	US#120/3,118 Sec#31/265
1M Return	11.77%	US#560/3,118 Sec#36/265
From 52W High	-8.98%	US#419/3,118 Sec#32/265
1Y MDD	-32.79%	US#1,496/3,118 Sec#77/265
Trading
Volume	1,819,212 shares	US#1,015/3,118 Sec#91/265
Trading Value	$47M	US#1,330/3,118 Sec#82/265
Per Share
EPS	$2.85	US#1,089/3,118 Sec#32/265
BPS	$9.36	US#1,889/3,118 Sec#74/265